Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Conditions
Keywords
Second line, Angiogenesis, Vascular endothelial growth factor receptor 2
Brief summary
The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.
Interventions
DRUGRamucirumab
Administered IV
DRUGPaclitaxel
Administered IV
DRUGPlacebo
Administered IV
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0 or 1 at study entry. * Have a histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma. * Have metastatic disease or locally advanced, unresectable disease. * Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. * Have experienced documented objective radiographic or symptomatic disease progression during first-line therapy, or within 4 months after the last dose of first-line therapy with any platinum/fluoropyrimidine doublet for unresectable or metastatic disease. * Have adequate organ function. * Have urinary protein ≤1+ on dipstick or routine urinalysis.
Exclusion criteria
* Have undergone major surgery within 28 days prior to randomization. * Have received any first-line chemotherapy other than platinum and fluoropyrimidine with or without anthracycline for advanced gastric or GEJ adenocarcinoma. * Have received any previous systemic therapy (including investigational agents) targeting vascular endothelial growth factor (VEGF) or the VEGF receptor signaling pathways. * Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to randomization. * Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry. * Have a history of GI perforation and/or fistulae within 6 months prior to randomization. * Have experienced any arterial thromboembolic event within 6 months prior to randomization. * Have uncontrolled arterial hypertension (systolic blood pressure ≥160 millimeters of mercury \[mmHg\] or diastolic blood pressure ≥100 mmHg) despite standard medical management. * Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to randomization. * Have a serious illness or medical condition(s).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Up To 30 Months) | PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
| Overall Survival (OS) | Randomization to Date of Death from Any Cause (Up To 37 Months) | OS defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Objective Response (DoR) | Date of Objective Response to the Date of the First Radiographically Documented Progressive Disease or Death Due to Any Cause (Up To 24 Months) | DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. |
| Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months) | EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. Least square (LS) mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline. |
| Time to Progression (TTP) | Randomization to the Date of the First Radiographically Documented Progressive Disease (Up To 30 Months) | TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s). |
| Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score | Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months) | EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. |
| Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score | Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months) | EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. The EQ-5D VAS is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). |
| Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months) | EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline. |
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | Randomization to Objective Disease Progression (Up To 30 Months) | ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. |
Countries
China, Malaysia, Philippines, Thailand
Participant flow
Pre-assignment details
In the Participant Flow, participants who completed were those who died on treatment or during follow-up.
Participants by arm
| Arm | Count |
|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel 8 mg/kg ramucirumab was administered as an IV on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.
Participants may continue on treatment until discontinuation criteria were met. | 294 |
| Placebo + 80 mg/m² Paclitaxel Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.
Participants may continue on treatment until discontinuation criteria were met. | 146 |
| Total | 440 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Discontinued from treatment but refused follow-up | 2 | 1 |
| Overall Study | Ended extension period | 3 | 0 |
| Overall Study | Enrolled/randomized, but never treated | 1 | 1 |
| Overall Study | Lost to Follow-up | 4 | 3 |
| Overall Study | Physician Decision | 0 | 2 |
| Overall Study | Sponsor Decision | 32 | 13 |
| Overall Study | Withdrawal by Subject | 6 | 3 |
Baseline characteristics
| Characteristic | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Total | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|---|
| Age, Continuous | 56.00 years STANDARD_DEVIATION 11.49 | 56.10 years STANDARD_DEVIATION 11.35 | 56.20 years STANDARD_DEVIATION 11.12 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 290 Participants | 435 Participants | 145 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 3 Participants | 4 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 1 Participants | 0 Participants |
| Region of Enrollment China | 257 Participants | 392 Participants | 135 Participants |
| Region of Enrollment Malaysia | 18 Participants | 25 Participants | 7 Participants |
| Region of Enrollment Philippines | 6 Participants | 8 Participants | 2 Participants |
| Region of Enrollment Thailand | 13 Participants | 15 Participants | 2 Participants |
| Sex: Female, Male Female | 89 Participants | 139 Participants | 50 Participants |
| Sex: Female, Male Male | 205 Participants | 301 Participants | 96 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 246 / 294 | 123 / 146 |
| other Total, other adverse events | 287 / 293 | 143 / 145 |
| serious Total, serious adverse events | 100 / 293 | 37 / 145 |
Outcome results
Primary
Overall Survival (OS)
OS defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Time frame: Randomization to Date of Death from Any Cause (Up To 37 Months)
Population: All randomized participants. Censored participants: Ramucirumab +Paclitaxel = 52, Placebo + Paclitaxel = 25.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Overall Survival (OS) | 8.71 Months |
| Placebo + 80 mg/m² Paclitaxel | Overall Survival (OS) | 7.92 Months |
95% CI: [0.771, 1.203]
Primary
Progression Free Survival (PFS)
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Up To 30 Months)
Population: All randomized participants. Censored participants: Ramucirumab +Paclitaxel = 67, Placebo + Paclitaxel = 16.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Progression Free Survival (PFS) | 4.14 Months |
| Placebo + 80 mg/m² Paclitaxel | Progression Free Survival (PFS) | 3.15 Months |
p-value: 0.018495% CI: [0.613, 0.955]Log Rank
Secondary
Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. Least square (LS) mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Population: All randomized participants who received at least one dose of study drug with baseline and post-baseline EORTC QLQ-C30 data at short term follow up for each EORTC QLQ-C30 items.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Cognitive functioning | 2.87 Units on a scale | Standard Error 0.84 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Pain | -6.89 Units on a scale | Standard Error 1.07 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Physical functioning | 1.09 Units on a scale | Standard Error 0.82 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Dyspnea | -2.18 Units on a scale | Standard Error 0.95 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Social functioning | 2.71 Units on a scale | Standard Error 1.19 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Insomnia | -5.73 Units on a scale | Standard Error 1.18 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Emotional functioning | 5.89 Units on a scale | Standard Error 0.9 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Appetite loss | -7.84 Units on a scale | Standard Error 1.3 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Fatigue | -4.20 Units on a scale | Standard Error 1.14 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Constipation | -6.35 Units on a scale | Standard Error 1.11 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Role functioning | 0.60 Units on a scale | Standard Error 1.13 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Diarrhea | -2.51 Units on a scale | Standard Error 0.86 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Nausea and vomiting | -4.84 Units on a scale | Standard Error 0.77 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Financial difficulties | -8.49 Units on a scale | Standard Error 1.6 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Global health status | 5.30 Units on a scale | Standard Error 1.18 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Financial difficulties | -8.12 Units on a scale | Standard Error 2.13 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Global health status | 8.43 Units on a scale | Standard Error 1.56 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Physical functioning | 1.20 Units on a scale | Standard Error 1.1 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Role functioning | 1.27 Units on a scale | Standard Error 1.49 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Emotional functioning | 4.72 Units on a scale | Standard Error 1.19 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Cognitive functioning | 2.12 Units on a scale | Standard Error 1.11 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Social functioning | 2.98 Units on a scale | Standard Error 1.59 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Fatigue | -5.63 Units on a scale | Standard Error 1.51 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Nausea and vomiting | -3.80 Units on a scale | Standard Error 1.03 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Pain | -7.01 Units on a scale | Standard Error 1.43 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Dyspnea | -2.65 Units on a scale | Standard Error 1.27 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Insomnia | -7.06 Units on a scale | Standard Error 1.57 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Appetite loss | -10.26 Units on a scale | Standard Error 1.73 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Constipation | -5.41 Units on a scale | Standard Error 1.48 |
| Placebo + 80 mg/m² Paclitaxel | Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Diarrhea | -3.03 Units on a scale | Standard Error 1.14 |
Secondary
Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. The EQ-5D VAS is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Population: All randomized participants who received at least one dose of study drug with baseline and post-baseline EQ-5D 3L data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score | -9.6 millimeter (mm) | Standard Deviation 20.11 |
| Placebo + 80 mg/m² Paclitaxel | Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score | -8.6 millimeter (mm) | Standard Deviation 15.88 |
Secondary
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Population: All randomized participants who received at least one dose of study drug with baseline and post-baseline EQ-5D 3L data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score | -0.1351 Units on a scale | Standard Deviation 0.2472 |
| Placebo + 80 mg/m² Paclitaxel | Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score | -0.1303 Units on a scale | Standard Deviation 0.1765 |
Secondary
Duration of Objective Response (DoR)
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Date of Objective Response to the Date of the First Radiographically Documented Progressive Disease or Death Due to Any Cause (Up To 24 Months)
Population: All randomized participants with response. Censored participants: Ramucirumab +Paclitaxel = 1, Placebo + Paclitaxel = 4.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Duration of Objective Response (DoR) | 4.34 Months |
| Placebo + 80 mg/m² Paclitaxel | Duration of Objective Response (DoR) | 2.83 Months |
95% CI: [0.577, 1.421]
Secondary
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization to Objective Disease Progression (Up To 30 Months)
Population: All randomized participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 26.5 Percentage of participants |
| Placebo + 80 mg/m² Paclitaxel | Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 21.9 Percentage of participants |
95% CI: [0.5, 1.2]
Secondary
Time to Progression (TTP)
TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
Time frame: Randomization to the Date of the First Radiographically Documented Progressive Disease (Up To 30 Months)
Population: All randomized participants. Censored participants: Ramucirumab +Paclitaxel = 98, Placebo + Paclitaxel = 36.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Time to Progression (TTP) | 4.27 Months |
| Placebo + 80 mg/m² Paclitaxel | Time to Progression (TTP) | 4.07 Months |
95% CI: [0.598, 0.968]
Secondary
Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Population: All randomized participants who received at least one dose of study drug with baseline and post-baseline EORTC QLQ-C30 data at short term follow up for each EORTC QLQ-C30 items.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Cognitive functioning | -13.66 Units on a scale | Standard Error 1.4 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Pain | 14.01 Units on a scale | Standard Error 1.5 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Physical functioning | -14.31 Units on a scale | Standard Error 1.3 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Dyspnea | 16.58 Units on a scale | Standard Error 1.51 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Social functioning | -17.05 Units on a scale | Standard Error 1.73 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Insomnia | 14.14 Units on a scale | Standard Error 1.74 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Emotional functioning | -9.80 Units on a scale | Standard Error 1.3 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Appetite loss | 17.06 Units on a scale | Standard Error 1.85 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Fatigue | 15.28 Units on a scale | Standard Error 1.36 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Constipation | 8.39 Units on a scale | Standard Error 1.57 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Role functioning | -18.46 Units on a scale | Standard Error 1.72 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Diarrhea | 13.41 Units on a scale | Standard Error 1.39 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Nausea and vomiting | 8.57 Units on a scale | Standard Error 1.46 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Financial difficulties | 10.11 Units on a scale | Standard Error 1.8 |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Global health status | -14.42 Units on a scale | Standard Error 1.32 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Financial difficulties | 9.32 Units on a scale | Standard Error 2.39 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Global health status | -9.83 Units on a scale | Standard Error 1.75 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Physical functioning | -11.71 Units on a scale | Standard Error 1.73 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Role functioning | -14.39 Units on a scale | Standard Error 2.28 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Emotional functioning | -6.77 Units on a scale | Standard Error 1.72 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Cognitive functioning | -12.08 Units on a scale | Standard Error 1.85 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Functional scale: Social functioning | -16.52 Units on a scale | Standard Error 2.3 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Fatigue | 10.17 Units on a scale | Standard Error 1.8 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Nausea and vomiting | 8.66 Units on a scale | Standard Error 1.95 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Pain | 10.11 Units on a scale | Standard Error 2 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Dyspnea | 8.34 Units on a scale | Standard Error 2.01 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Insomnia | 7.97 Units on a scale | Standard Error 2.32 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Appetite loss | 11.11 Units on a scale | Standard Error 2.46 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Constipation | 6.58 Units on a scale | Standard Error 2.08 |
| Placebo + 80 mg/m² Paclitaxel | Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Symptom scale: Diarrhea | 5.67 Units on a scale | Standard Error 1.85 |